Damodaran Narayanan

TP 53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS / AML Tracking no : ADV-2021-006239 R 2

P. Cin, O. Weinberg, J. Gagan, 2022 .

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML

P. D. Dal Cin, D. Arber, O. Weinberg, 2022, Blood advances.

Tocilizumab for treatment of cutaneous and systemic manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome without myelodysplastic syndrome

W. Wong, S. Ritter, A. Goyal, 2022, JAAD case reports.

NPM1 mutations may be associated with adverse outcome in the setting of myeloid neoplasms with complex karyotype.

G. Pinkus, P. Cin, A. Bagg, 2022, Leukemia research.

Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group

Philipp W. Raess, G. Pinkus, A. Bagg, 2023, Leukemia & lymphoma.

Initial Diagnosis of Classic Hodgkin Lymphoma With Skin Biopsy: A Rare Case and Review of Diagnostic Considerations.

G. Pinkus, A. Goyal, Damodaran Narayanan, 2023, The American Journal of dermatopathology.

A Case Study in Process Improvement to Minimize Delays from Obtaining Blood for Red Cell Exchange for a Patient with Sickle Cell Disease and Multiple Red Blood Cell Alloantibodies

W. N. Rose, Damodaran Narayanan, K. Schaser, 2022, Case reports in hematology.